Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma
Conclusion:The addition of nimotuzumab to CCRT after IC in LANPC has shown promising results in improving treatment outcomes and acceptable toxicities.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Gastroenterology | Hematology | Nasopharyngeal Cancer | Toxicology